ClinicalTrials.Veeva

Menu

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

Stanford University logo

Stanford University

Status and phase

Completed
Phase 2

Conditions

Blood and Marrow Transplant (BMT)
Lymphomas: Non-Hodgkin
Lymphoma, Non-Hodgkin

Treatments

Procedure: ablative allogeneic hematopoietic cell transplantation

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00186394
NCT00186394
76679
BMT4L

Details and patient eligibility

About

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

Full description

To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.

Enrollment

35 estimated patients

Sex

All

Ages

18 to 61 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma

Age: >18 and <61 years of age

Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum transaminases >2.5X normal values

Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min

Diseases other than non-Hodgkin's lymphoma

Prior bone marrow transplant procedure

Severe psychological or medical illness

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems